

# Bob W Van Oosten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9353476/publications.pdf>

Version: 2024-02-01

57  
papers

4,744  
citations

182225

30  
h-index

156644

58  
g-index

61  
all docs

61  
docs citations

61  
times ranked

5024  
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1121-1125.	1.4	34
2	Natalizumab concentrations during pregnancy in three patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 323-326.	1.4	1
3	Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 275-283.	4.9	34
4	Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101467.	0.9	2
5	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 9-14.	0.9	22
6	Personalized extended interval dosing of natalizumab in MS. <i>Neurology</i> , 2020, 95, e745-e754.	1.5	36
7	Fecal Microbiota Transplantation in Neurological Disorders. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 98.	1.8	221
8	Response: Brain military enhancement. <i>Neuroradiology</i> , 2020, 62, 547-547.	1.1	0
9	Brain military enhancement. <i>Neuroradiology</i> , 2020, 62, 283-300.	1.1	16
10	Emerging safety issues in alemtuzumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1206-1208.	1.4	18
11	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2019, 86, 322-324.	2.8	11
12	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1027-1038.	0.9	51
13	Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and $\alpha$ 4-integrin receptor saturation. <i>Journal of Neurology</i> , 2019, 266, 1804-1805.	1.8	2
14	Disease activity following pregnancy-related discontinuation of natalizumab in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e424.	3.1	15
15	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	6.3	684
16	Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1542-1553.	1.4	47
17	Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1527-1541.	1.4	45
18	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. <i>Journal of Neurology</i> , 2017, 264, 1155-1164.	1.8	77

#	ARTICLE	IF	CITATIONS
19	Time is vision in recurrent optic neuritis. <i>Brain Research</i> , 2017, 1673, 95-101.	1.1	14
20	Neuromyelitis optica spectrum disorder mimicking multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 54-56.	0.9	2
21	The role of appraisal and coping style in relation with societal participation in fatigued patients with multiple sclerosis: a cross-sectional multiple mediator analysis. <i>Journal of Behavioral Medicine</i> , 2016, 39, 855-865.	1.1	9
22	Real-Time Assessment of Fatigue in Patients With Multiple Sclerosis: How Does It Relate to Commonly Used Self-Report Fatigue Questionnaires?. <i>Archives of Physical Medicine and Rehabilitation</i> , 2016, 97, 1887-1894.e1.	0.5	19
23	Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , 2015, 21, 481-484.	1.4	18
24	PML in Patients Treated with Dimethyl Fumarate. <i>New England Journal of Medicine</i> , 2015, 373, 582-584.	13.9	17
25	Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. <i>Journal of Neurology</i> , 2015, 262, 65-73.	1.8	44
26	PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate. <i>New England Journal of Medicine</i> , 2015, 372, 1474-1476.	13.9	144
27	MRI pattern in asymptomatic natalizumab-associated PML. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 793-798.	0.9	75
28	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. <i>Journal of Neurology</i> , 2014, 261, 1139-1143.	1.8	30
29	The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. <i>Trials</i> , 2013, 14, 250.	0.7	41
30	PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy. <i>New England Journal of Medicine</i> , 2013, 368, 1658-1659.	13.9	181
31	What Went Wrong? the Flawed Concept of Cerebrospinal Venous Insufficiency. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 657-668.	2.4	51
32	Case Reports of PML in Patients Treated for Psoriasis. <i>New England Journal of Medicine</i> , 2013, 369, 1080-1082.	13.9	45
33	Tumefactive multiple sclerosis lesions under fingolimod treatment. <i>Neurology</i> , 2012, 79, 2000-2003.	1.5	79
34	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. <i>Methods</i> , 2012, 56, 508-513.	1.9	38
35	Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. <i>Neurology</i> , 2011, 76, 574-576.	1.5	27
36	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 429-435.	0.9	119

#	ARTICLE	IF	CITATIONS
37	Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. <i>Annals of Neurology</i> , 2010, 68, 392-395.	2.8	120
38	Steroid-responsive edema in CAA-related inflammation. <i>Journal of Neurology</i> , 2009, 256, 285-286.	1.8	8
39	Whipple's disease in mentally retarded patients: Report of two cases. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 1071-1073.	1.5	0
40	Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG. <i>NeuroImage</i> , 2006, 29, 783-788.	2.1	73
41	The role of spinal cord imaging in the diagnosis of multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 283-286.	2.7	3
42	Effect of rimonabant on weight reduction and cardiovascular risk. <i>Lancet</i> , The, 2005, 366, 367-368.	6.3	15
43	Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. <i>Multiple Sclerosis Journal</i> , 2004, 10, 330-332.	1.4	33
44	Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. <i>Annals of Neurology</i> , 1999, 45, 695-703.	2.8	247
45	Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis. <i>Archives of Neurology</i> , 1999, 56, 345.	4.9	63
46	Choosing Drug Therapy for Multiple Sclerosis. <i>Drugs</i> , 1998, 56, 555-569.	4.9	13
47	Increased Production of Tumor Necrosis Factor $\hat{1}\pm$ , and Not of Interferon $\hat{1}^3$ , Preceding Disease Activity in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 1998, 55, 793.	4.9	60
48	Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial. <i>Neurology</i> , 1997, 49, 351-357.	1.5	247
49	Interleukin-2 therapy does not exacerbate multiple sclerosis. <i>Neurology</i> , 1997, 49, 633-634.	1.5	5
50	TNF- $\hat{1}\pm$ promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. <i>Journal of Neuroimmunology</i> , 1997, 72, 149-153.	1.1	214
51	Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.. <i>Journal of Clinical Investigation</i> , 1997, 99, 2225-2231.	3.9	85
52	A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1996, 66, 49-55.	1.1	22
53	Accumulation of hypointense lesions ("black holes") on T <sub>1</sub> spin-echo MRI correlates with disease progression in multiple sclerosis. <i>Neurology</i> , 1996, 47, 1469-1476.	1.5	440
54	Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. <i>Neurology</i> , 1996, 47, 1531-1534.	1.5	705

#	ARTICLE	IF	CITATIONS
55	A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Multiple Sclerosis Journal, 1996, 1, 339-342.	1.4	27
56	Multiple Sclerosis Therapy. Drugs, 1995, 49, 200-212.	4.9	22
57	Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet, The, 1995, 346, 979-980.	6.3	69